SLU-PP-332
Also known as: Exercise Mimetic, ERR Agonist
Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator
Overview
Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.
Key benefits
- Exercise mimetic effects without physical activity
- 12% weight loss in 28 days
- 70% increased endurance
- 25% enhanced fatty acid oxidation
- Improved insulin sensitivity
- Reduced hepatic steatosis
- Cardiac protection
- Reversal of age-related mitochondrial dysfunction
Mechanism of action
Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.
Molecular data
- Type
- Synthetic ERR agonist
- Half-life
- Under investigation (no human PK data)
Sequence
(E)-4-Hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide
Indications
What the research community uses this compound for, with self-reported effectiveness.
Metabolic Health
Exercise Performance
Cardiovascular
Anti-Aging
Kidney Protection
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 50 mg/kg (animal dosing) | Twice daily | — |
| — | 50 mg/kg (animal dosing) | Single dose 1 hour pre-exercise | — |
| — | 50 mg/kg (animal dosing) | Twice daily for 4-8 weeks | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Animal studies show favorable safety with no severe effects at therapeutic doses
- Well-tolerated in rodents and canines
- No liver, kidney, or cardiac toxicity documented
- No lean mass loss
- Does not suppress hormones or act as stimulant
- Minor plasma cholesterol and liver enzyme changes in some studies
Contraindications
- NOT FOR HUMAN USE - no approved human dose
- No human clinical trials conducted
- Potential interaction with diabetes medications
Monitoring
- Blood glucose if combined with insulin or metformin
- Weight loss rate if combined with other weight loss compounds
- Metabolic parameters in extended use
- Cardiac function if cardiac history present
References
Primary literature and clinical-trial data informing this entry.